FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients — Live Feedhttps://www.live-feeds.com/feed/fda-approves-daily-hiv-pill-from-gilead-designed-to-simplify-treatment-for-some-patientsContinuously updated, source-cited coverage. FDA approves Gilead single-pill HIV treatment Bixlenvohttps://www.live-feeds.com/feed/fda-approves-daily-hiv-pill-from-gilead-designed-to-simplify-treatment-for-some-patientshttps://www.live-feeds.com/feed/fda-approves-daily-hiv-pill-from-gilead-designed-to-simplify-treatment-for-some-patients#u52058Sun, 30 Aug 2026 06:10:14 +0000The U.S. FDA approved Bixlenvo, a once-daily single tablet from Gilead Sciences for virologically suppressed adults with HIV. The medication combines bictegravir and lenacapavir into one pill. It is specifically designed for patients on complex regimens or those who cannot use existing single-tablet options. By consolidating treatment into one daily dose, the drug aims to simplify the medication process for adults who have already achieved viral suppression but require a more streamlined therapeutic approach.Why it mattersManaging HIV often requires strict adherence to medication to maintain v